Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer
View abstract on PubMed
Summary
This summary is machine-generated.Epigenetic differences within colorectal tumors, or intratumor heterogeneity, impact patient survival. Lower heterogeneity in DNA methylation patterns correlates with shorter relapse-free and overall survival times in colorectal cancer patients.
Area Of Science
- Oncology
- Epigenetics
- Genomics
Background
- Colorectal cancer (CRC) lacks validated biomarkers for outcome prediction.
- Tumor heterogeneity, both inter- and intra-tumor, presents a significant challenge.
- Epigenetic modifications, specifically DNA methylation, offer a dynamic approach to study intratumor heterogeneity.
Purpose Of The Study
- To investigate intratumor heterogeneity at the DNA methylation level in colorectal tumors.
- To correlate DNA methylation patterns with clinical outcomes, including relapse-free and overall survival.
Main Methods
- Analyzed DNA methylation profiles of over 450,000 CpG sites across three macrodissected regions of 79 colorectal tumors and 23 liver metastases.
- Performed analyses for KRAS and BRAF mutations, single nucleotide polymorphisms, and immunohistochemistry.
- Quantified intratumor heterogeneity using individual coefficients for DNA methylation patterns.
Main Results
- Significant differences in DNA methylation were observed among tumor sections, with tumor-host interface regions showing the most variation.
- Tumor samples near the gastrointestinal tract shared more methylation events with metastases.
- Lower levels of epigenetic homogeneity (higher heterogeneity) were significantly associated with longer relapse-free and overall survival.
Conclusions
- Intratumor heterogeneity in DNA methylation patterns is a significant feature of colorectal cancer.
- The degree of DNA methylation heterogeneity within a tumor correlates with patient survival outcomes.
- Epigenetic heterogeneity may serve as a potential prognostic biomarker for colorectal cancer.